X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17043) 17043
Book Chapter (23) 23
Dissertation (9) 9
Book / eBook (8) 8
Magazine Article (5) 5
Conference Proceeding (2) 2
Publication (2) 2
Newsletter (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (13917) 13917
neuroprotective agents - pharmacology (9092) 9092
male (9003) 9003
rats (7793) 7793
neurosciences (7524) 7524
neuroprotective agents - therapeutic use (6048) 6048
humans (5848) 5848
neuroprotection (5059) 5059
disease models, animal (4403) 4403
neuroprotective agents - administration & dosage (4217) 4217
mice (4034) 4034
rats, sprague-dawley (3861) 3861
brain (3731) 3731
oxidative stress (3419) 3419
female (3192) 3192
neurology (3124) 3124
neurons - drug effects (2954) 2954
apoptosis (2756) 2756
pharmacology & pharmacy (2695) 2695
rats, wistar (2584) 2584
neurons (2437) 2437
brain - drug effects (2268) 2268
clinical neurology (2180) 2180
ischemia (2067) 2067
stroke (2028) 2028
dose-response relationship, drug (2007) 2007
analysis (1980) 1980
biochemistry & molecular biology (1917) 1917
apoptosis - drug effects (1894) 1894
oxidative stress - drug effects (1694) 1694
neurons - metabolism (1680) 1680
brain - metabolism (1636) 1636
inflammation (1535) 1535
time factors (1528) 1528
cell biology (1513) 1513
mice, inbred c57bl (1487) 1487
rodents (1476) 1476
cells, cultured (1406) 1406
alzheimers-disease (1405) 1405
biomedicine (1395) 1395
expression (1386) 1386
hippocampus - drug effects (1375) 1375
brain - pathology (1373) 1373
treatment outcome (1373) 1373
neurons - pathology (1331) 1331
brain ischemia - drug therapy (1258) 1258
alzheimer's disease (1218) 1218
parkinson's disease (1211) 1211
activation (1193) 1193
neuroprotective agents (1183) 1183
antioxidants (1177) 1177
cell survival - drug effects (1153) 1153
neurodegeneration (1140) 1140
rat (1127) 1127
research (1126) 1126
cell-death (1080) 1080
neurotoxicity (1061) 1061
hippocampus (1030) 1030
signal transduction - drug effects (997) 997
injuries (990) 990
health aspects (982) 982
immunohistochemistry (970) 970
in-vitro (969) 969
proteins (962) 962
injury (941) 941
hippocampus - metabolism (899) 899
behavior, animal - drug effects (882) 882
glutamate (875) 875
motor activity - drug effects (865) 865
brain ischemia - pathology (864) 864
cell death - drug effects (863) 863
cerebral ischemia (854) 854
cerebral-ischemia (845) 845
in-vivo (836) 836
inhibition (835) 835
middle aged (833) 833
antioxidants - pharmacology (831) 831
care and treatment (826) 826
neuroprotective agents - metabolism (824) 824
neurodegenerative diseases (823) 823
parkinsons-disease (814) 814
focal cerebral-ischemia (813) 813
maze learning - drug effects (774) 774
nervous system (771) 771
hippocampus - pathology (765) 765
physiological aspects (765) 765
damage (759) 759
mechanisms (748) 748
memory (747) 747
animals, newborn (743) 743
cell death (736) 736
adult (734) 734
random allocation (733) 733
stroke - drug therapy (726) 726
traumatic brain injury (721) 721
cells (718) 718
endocrinology & metabolism (718) 718
neuroprotective agents - chemistry (716) 716
alzheimer disease - drug therapy (706) 706
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16842) 16842
Russian (233) 233
Japanese (141) 141
Chinese (98) 98
German (65) 65
Spanish (32) 32
French (29) 29
Portuguese (19) 19
Hungarian (16) 16
Polish (12) 12
Ukrainian (10) 10
Danish (6) 6
Czech (4) 4
Norwegian (4) 4
Swedish (4) 4
Catalan (1) 1
Dutch (1) 1
Finnish (1) 1
Korean (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Trends in molecular medicine, ISSN 1471-4914, 2012, Volume 18, Issue 6, pp. 337 - 347
Glucosinolates and isothiocyanates have both been objects of research for more than half a century. Interest in these unique phytochemicals escalated following... 
Pathology | PHENETHYL ISOTHIOCYANATE | MEDICINE, RESEARCH & EXPERIMENTAL | MIGRATION INHIBITORY FACTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | BENZYL ISOTHIOCYANATE | CRUCIFEROUS VEGETABLES | SULFORAPHANE RESTORES | CELL BIOLOGY | TRANSCRIPTION FACTOR NRF2 | TRAUMATIC BRAIN-INJURY | INTRACEREBRAL HEMORRHAGE | SPINAL-CORD-INJURY | BROCCOLI SPROUT BEVERAGES | Cardiovascular Diseases - drug therapy | Humans | Isothiocyanates - administration & dosage | Diabetic Nephropathies - drug therapy | Glucosinolates - chemistry | Neuroprotective Agents - pharmacology | Anticarcinogenic Agents - administration & dosage | Isothiocyanates - chemistry | Anti-Bacterial Agents - chemistry | Helicobacter Infections - drug therapy | Models, Animal | Neuroprotective Agents - administration & dosage | Anticarcinogenic Agents - pharmacology | Isothiocyanates - pharmacology | Neuroprotective Agents - chemistry | Cardiotonic Agents - chemistry | Cardiotonic Agents - pharmacology | Animals | Anticarcinogenic Agents - chemistry | Cardiotonic Agents - administration & dosage | Glucosinolates - pharmacology | Central Nervous System - drug effects | Anti-Bacterial Agents - pharmacology | Cell Transformation, Neoplastic - drug effects | Anti-Bacterial Agents - administration & dosage | Glucosinolates - administration & dosage | Skin - drug effects | Proteins | Analysis
Journal Article
Journal of controlled release, ISSN 0168-3659, 2015, Volume 207, pp. 18 - 30
Exosomes are naturally occurring nanosized vesicles that have attracted considerable attention as drug delivery vehicles in the past few years. Exosomes are... 
Oxidative stress | Neuroinflammation | Parkinson's disease | Catalase | Exosomes | Blood–brain barrier | Blood-brain barrier | ALZHEIMERS-DISEASE | REPEATED INJECTIONS | MACROPHAGE DELIVERY | MEDIATED TRANSFER | BLOOD-BRAIN-BARRIER | BIOLOGICAL BARRIERS | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | PEGYLATED LIPOSOMES | PHARMACOLOGY & PHARMACY | SUPEROXIDE-DISMUTASE | Antioxidants - chemistry | Antioxidants - metabolism | Oxidopamine | Anti-Inflammatory Agents - metabolism | PC12 Cells | Neuroprotective Agents - metabolism | Drug Carriers | Brain - metabolism | Nanoparticles | Parkinsonian Disorders - metabolism | Parkinsonian Disorders - drug therapy | Antiparkinson Agents - chemistry | Anti-Inflammatory Agents - administration & dosage | Female | Neurons - metabolism | Neuroprotective Agents - administration & dosage | Nanomedicine | Disease Models, Animal | Neuroprotective Agents - chemistry | Mice, Inbred C57BL | Solubility | Rats | Technology, Pharmaceutical - methods | Parkinsonian Disorders - chemically induced | Administration, Intranasal | Chemistry, Pharmaceutical | Brain - drug effects | Catalase - metabolism | Catalase - administration & dosage | Animals | Anti-Inflammatory Agents - chemistry | Antioxidants - administration & dosage | RAW 264.7 Cells | Antiparkinson Agents - administration & dosage | Mice | Kinetics | Oxidative Stress - drug effects | Antiparkinson Agents - metabolism | Catalase - chemistry | Drugs | Drug delivery systems | Proteases | Analysis | Antiparkinsonian agents | Vehicles | blood-brain barrier | neuroinflammation | exosomes | catalase | oxidative stress | Parkinson’s disease
Journal Article
Progress in neuro-psychopharmacology & biological psychiatry, ISSN 0278-5846, 04/2013, Volume 42, pp. 135 - 145
Journal Article
Current pharmaceutical design, ISSN 1381-6128, 02/2011, Volume 17, Issue 5, pp. 489 - 507
Journal Article
Clinical therapeutics, ISSN 0149-2918, 2007, Volume 29, Issue 9, pp. 1825 - 1849
Abstract Background: Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both... 
Internal Medicine | Medical Education | rasagiline | Parkinson's disease | propargylamine | neuroprotection | monoamine oxidase | selegiline | CONTROLLED-TRIAL | SEROTONIN SYNDROME | MAO-B INHIBITOR | MPTP-INDUCED NEUROTOXICITY | MOTOR FLUCTUATIONS | MITOCHONDRIAL PERMEABILITY TRANSITION | IN-VIVO | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | L-DEPRENYL | NEUROBLASTOMA SH-SY5Y CELLS | rasagilme | Indans - adverse effects | Neuroprotective Agents - therapeutic use | Antiparkinson Agents - pharmacology | Humans | Selegiline - pharmacology | Parkinson Disease - drug therapy | Indans - therapeutic use | Monoamine Oxidase Inhibitors - administration & dosage | Antiparkinson Agents - therapeutic use | Drug Interactions | Neuroprotective Agents - pharmacology | Indans - administration & dosage | Neuroprotective Agents - adverse effects | Drug Therapy, Combination | Neuroprotective Agents - administration & dosage | Selegiline - therapeutic use | Monoamine Oxidase Inhibitors - therapeutic use | Monoamine Oxidase Inhibitors - pharmacology | Selegiline - adverse effects | Monoamine Oxidase Inhibitors - adverse effects | Food-Drug Interactions | Antiparkinson Agents - adverse effects | Selegiline - administration & dosage | Antiparkinson Agents - administration & dosage | Indans - pharmacology | Oxidases | Medical colleges | Drug therapy | Analysis
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 01/2006, Volume 26, Issue 2, pp. 662 - 670
.... We report here that daily oral administration to mice of the brain-penetrant compound 4,6-diphenyl-3-(4-(pyrimidin-2-yl)piperazin-1-yl)pyridazine (MW01-5-188WH... 
Neuroinflammation | Behavior | Cytokines | Glia | Neurodegeneration | Alzheimer's disease | ACTIVATION | ALZHEIMERS-DISEASE | DRUG DISCOVERY | neurodegeneration | glia | NEUROSCIENCES | neuroinflammation | ROFECOXIB | cytokines | NEUROPATHOLOGY | behavior | DEFICITS | AMINOPYRIDAZINES | PROGRESSION | TRANSGENIC MICE | Single-Blind Method | Microglia - metabolism | Humans | Microsomes, Liver - metabolism | Tumor Necrosis Factor-alpha - genetics | Depression, Chemical | Interleukin-1 - biosynthesis | Brain - metabolism | S100 Proteins - genetics | Neuroprotective Agents - pharmacokinetics | Amyloid beta-Peptides - administration & dosage | S100 Proteins - biosynthesis | Cytokines - genetics | Cells, Cultured - drug effects | S100 Calcium Binding Protein beta Subunit | Administration, Oral | Rats | Piperazines - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - toxicity | Brain - drug effects | Nerve Growth Factors - genetics | Peptide Fragments - antagonists & inhibitors | Lipopolysaccharides - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Pyridazines - pharmacokinetics | Cells, Cultured - metabolism | Mice | Tumor Necrosis Factor-alpha - biosynthesis | Astrocytes - metabolism | Neuroprotective Agents - therapeutic use | Piperazines - administration & dosage | Interleukin-1 - genetics | Peptide Fragments - toxicity | Biological Availability | Piperazines - toxicity | Hippocampus - drug effects | Nerve Degeneration - prevention & control | Pyridazines - administration & dosage | Female | Piperazines - pharmacokinetics | Drug Evaluation, Preclinical | Neuroprotective Agents - administration & dosage | Chemical and Drug Induced Liver Injury - etiology | Pyridazines - therapeutic use | Astrocytes - drug effects | Microglia - drug effects | Plaque, Amyloid - pathology | Amyloid beta-Peptides - toxicity | Mice, Inbred C57BL | Peptide Fragments - administration & dosage | Infusions, Parenteral | Neuroprotective Agents - toxicity | Maze Learning - drug effects | Nerve Growth Factors - biosynthesis | Pyridazines - toxicity | Gene Expression Regulation - drug effects | Hippocampus - metabolism | Amyloid beta-Peptides - antagonists & inhibitors | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Hippocampus - physiology | Cytokines - biosynthesis | Neurobiology of Disease
Journal Article
Biomaterials, ISSN 0142-9612, 2013, Volume 34, Issue 15, pp. 3870 - 3881
...–brain barrier (BBB) greatly limits their penetration for action in the brain following parenteral administration [5]. Intranasal administration provides a non... 
Advanced Basic Science | Dentistry | Lactoferrin | Brain targeting | Intranasal administration | NAP | Nanoparticle | Alzheimer's disease | MATERIALS SCIENCE, BIOMATERIALS | GENE DELIVERY | DRUG-DELIVERY | PLA NANOPARTICLES | ENGINEERING, BIOMEDICAL | ALZHEIMERS-DISEASE | CELL-PENETRATING PEPTIDES | NEUROPROTECTIVE PROTEIN ADNP | AMYLOID BETA-PEPTIDE | CENTRAL-NERVOUS-SYSTEM | IBOTENIC ACID | PLGA NANOPARTICLES | Thiazoles - blood | Nanoparticles - chemistry | Humans | Ibotenic Acid - pharmacology | Brain - enzymology | Molecular Sequence Data | Carbocyanines - metabolism | Male | Polyethylene Glycols - chemistry | Choline O-Acetyltransferase - metabolism | Peptides - administration & dosage | Thiazoles - pharmacokinetics | Drug Delivery Systems | Brain - metabolism | Neuroprotective Agents - pharmacology | Amyloid beta-Peptides - administration & dosage | Neuroprotective Agents - administration & dosage | Amino Acid Sequence | Cell Line | Lactoferrin - metabolism | Tissue Distribution - drug effects | Neuroprotective Agents - chemistry | Peptides - chemistry | Amyloid beta-Peptides - toxicity | Endocytosis - drug effects | Coumarins - pharmacokinetics | Nanoparticles - ultrastructure | Administration, Intranasal | Rats, Sprague-Dawley | Mice, Inbred ICR | Peptides - pharmacology | Brain - drug effects | Coumarins - pharmacology | Polyesters - chemistry | Animals | Coumarins - blood | Brain - pathology | Mice | Thiazoles - pharmacology | Acetylcholinesterase - metabolism | Nanoparticles | Drugs | Drug delivery systems | Clathrin | Peptides | Analysis | Lactoferrins | Amyloid beta-protein | Drugstores | Protein binding | Vehicles | Proteins | Brain | X-ray photoelectron spectroscopy | Hippocampus
Journal Article
The Journal of biological chemistry, ISSN 1083-351X, 2017, Volume 292, Issue 45, pp. 18486 - 18499
The cornea is densely innervated to sustain the integrity of the ocular surface. Corneal nerve damage produced by aging, diabetes, refractive surgeries, and... 
EXPERIMENTAL SURGERY | phospholipase A | cornea | BIOCHEMISTRY & MOLECULAR BIOLOGY | brain-derived neurotrophic factor (BDNF) | neuropeptides | SPINAL-CORD | NGF | IDENTIFICATION | SENSORY NEURONS | PEDF | adipose triglyceride lipase | Sema7A | DRY EYE | INFLAMMATION | PEDF PLUS DHA | GROWTH-FACTOR | DHA | C-JUN | lipid signaling | Male | Receptors, Neuropeptide - metabolism | Eye Proteins - agonists | Trigeminal Ganglion - drug effects | Neuroprotective Agents - metabolism | Enzyme Inhibitors - administration & dosage | Nerve Growth Factors - pharmacology | Neuroprotective Agents - pharmacology | Cornea - pathology | Eye Proteins - antagonists & inhibitors | Organ Culture Techniques | Docosahexaenoic Acids - therapeutic use | Trigeminal Ganglion - pathology | Nerve Tissue Proteins - agonists | Trigeminal Nerve Injuries - drug therapy | Enzyme Inhibitors - pharmacology | Injections, Intraperitoneal | Nerve Growth Factors - administration & dosage | Serpins - pharmacology | Nerve Growth Factors - therapeutic use | Eye Proteins - metabolism | Nerve Regeneration - drug effects | Cornea - innervation | Eye Proteins - pharmacology | Neuroprotective Agents - therapeutic use | Administration, Ophthalmic | Cornea - physiology | Cornea - drug effects | Eye Proteins - administration & dosage | Receptors, Neuropeptide - agonists | Eye Proteins - genetics | Drug Therapy, Combination | Neuroprotective Agents - administration & dosage | Trigeminal Ganglion - physiology | Nerve Tissue Proteins - antagonists & inhibitors | Mice, Inbred C57BL | Receptors, Neuropeptide - antagonists & inhibitors | Trigeminal Nerve - pathology | Eye Proteins - therapeutic use | Serpins - therapeutic use | Docosahexaenoic Acids - administration & dosage | Nerve Tissue Proteins - genetics | Serpins - administration & dosage | Gene Expression Regulation - drug effects | Nerve Tissue Proteins - metabolism | Trigeminal Nerve - drug effects | Trigeminal Nerve - physiology | Animals | Phenylurea Compounds - administration & dosage | Phenylurea Compounds - pharmacology | Models, Neurological | Docosahexaenoic Acids - metabolism | Neurobiology
Journal Article